COVID-19 treatment: real-time analysis of 6,761 studies

17 million hours of research for 227 treatments shows that COVID-19 was avoidable. Direct treatment to the respiratory tract minimizes transmission and progression. Many systemic treatments and lifestyle choices reduce risk. Adoption of effective treatments was very slow, inconsistent, and biased towards high-profit.

Key results

Expand

Treatment delay (days since onset) Efficacy Early treatment is more effective 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 -25% 0% 25% 50% 75% 100% c19early.org November 2026 p<0.00000000001 mixed-effects meta-regression, most serious sufficiently powered outcome
Expand

RdRp Mpro COVID-19 treatments 12,000+ compounds 500+ therapeutic targets c19early.org November 2026 High-profit drugs molnupiravir remdesivir paxlovid
Expand

When treatments were shown effective

The time when clinical studies showed statistically significant efficacy or harm

November 2026
57treatments with a significant effect (2 harmful)
34also shown effective in RCTs alone so far
8+months delay for RCT confirmation
4+months delay for specific outcome confirmation (8+ for RCTs alone)
20202021202220232024202520262027RCT delayOutcome delay
HCQ10 mo2 mo
Zinc9 mo13 mo
Ivermectin4 mo1 mo
Metformin24 mo-
Colchicine16 mo0 mo
PPIshigher risk76+ mo11 mo
Vitamin C7 mo0 mo
Antiandrogens15 mo12 mo
Vitamin D12 mo14 d
Exercise74+ mo1 mo
Acetaminophenhigher risk73+ mo5 mo
H1RAs73+ mo2 mo
NAC4 mo4 mo
Curcumin3 mo2 mo
Sleep69+ mo0 mo
Melatonin18 mo5 mo
Diet67+ mo3 mo
Budesonide64+ mo4 mo
Fluvoxamine22 mo12 mo
Montelukast10 mo8 mo
Phthalocyanine18 mo61+ mo
Sunlight60+ mo4 mo
Quercetin0 mo12 mo
Spironolactone59+ mo13 mo
Vitamin B1258+ mo58+ mo
Regdanvimab57+ mo0 mo
Paxlovid55+ mo4 d
Tixagevimab/c..55+ mo0 mo
NaCl0 mo11 mo
Artemisinin50+ mo50+ mo
Chlorpheniramine48+ mo48+ mo
Azvudine47+ mo6 mo
Mebendazole43+ mo43+ mo
Sotrovimab43+ mo-
Vitamin A11 mo-
Nafamostat-38+ mo
Chlorhexidine0 mo17 mo
Thermotherapy0 mo36+ mo
SA5836+ mo0 mo
Niclosamide0 mo17+ mo
Azelastine16+ mo16+ mo
Leritrelvir2+ mo0 mo

all studies   RCTs only   delay   RCTs alone not yet significant  ·  blue : pooled outcomes   grey : specific outcomes  ·  higher risk red: meta-analysis shows harm  ·  efficacy: ≥10% improvement, p < 0.05, ≥3 studies  ·  harm: RR > 1.0, p < 0.05, ≥3 studies

Timeline for when studies showed efficacy - details and limitations. 0.4% of treatments show efficacy.
Expand

Protocol efficacy and cost by country

Treatment protocols varied widely

November 2026
Efficacy of protocol
SeychellesSCIcelandISBelizeBZMaltaMTLuxembourgLUMontenegroMEBhutanBTGuyanaGYComorosKMFijiFJDjiboutiDJCyprusCYMauritiusMUEstoniaEETrinidad and TobagoTTEquatorial GuineaGQBahrainBHLatviaLVGuinea-BissauGWSloveniaSINorth MacedoniaMKLesothoLSGabonGABotswanaBWGambiaGMNamibiaNALithuaniaLTAlbaniaALQatarQAJamaicaJMArmeniaAMMongoliaMNBosnia and HerzegovinaBAUruguayUYEritreaERGeorgiaGECroatiaHRPanamaPAMauritaniaMRNew ZealandNZCentral African RepublicCFIrelandIELiberiaLRCosta RicaCRNorwayNOSlovakiaSKCongoCGFinlandFIDenmarkDKSingaporeSGEl SalvadorSVKyrgyzstanKGNicaraguaNILebanonLBLibyaLYBulgariaBGParaguayPYHong KongHKSierra LeoneSLTogoTGSwitzerlandCHIsraelILSerbiaRSPapua New GuineaPGAustriaATBelarusBYTajikistanTJHungaryHUUnited Arab EmiratesAEHondurasHNSwedenSEAzerbaijanAZPortugalPTJordanJOGreeceGRCzechiaCZDominican RepublicDOSouth SudanSSCubaCUHaitiHTBelgiumBEBoliviaBOTunisiaTNBurundiBIBeninBJRwandaRWGuineaGNZimbabweZWChadTDCambodiaKHSenegalSNNetherlandsNLSyriaSYEcuadorECGuatemalaGTZambiaZMKazakhstanKZMalawiMWRomaniaROMaliMLBurkina FasoBFSri LankaLKTaiwanTWNigerNEAustraliaAUCôte d'IvoireCICameroonCMMadagascarMGVenezuelaVENepalNPYemenYEGhanaGHMozambiqueMZMalaysiaMYAngolaAOPeruPEUzbekistanUZSaudi ArabiaSAMoroccoMACanadaCAPolandPLAfghanistanAFIraqIQUkraineUASudanSDAlgeriaDZArgentinaARUgandaUGSpainESColombiaCOSouth KoreaKRKenyaKEMyanmarMMSouth AfricaZAItalyITFranceFRUnited KingdomGBThailandTHGermanyDEIranIRTurkeyTRDR CongoCDVietnamVNEgyptEGPhilippinesPHEthiopiaETJapanJPMexicoMXRussiaRUBangladeshBDNigeriaNGBrazilBRPakistanPKIndonesiaIDUSAUSIndiaINChinaCNmore effective, cheaperless effective, costlier
0%20%40%60%
$0$500$1,000$1,500$2,000
Cost per course

Cost and estimated efficacy of national COVID-19 protocols; area is proportional to population. Countries are named where there is room, with more populous countries first and in darker type; hover any dot for details.

Expand

Media covered only 0.8% of studies showing significantly lower COVID-19 risk

Only 5 positive studies were covered

0.8%

34 negative studies were covered

4%
5.4×
Negative bias for low-cost treatments
negative studies were 5.4 times more likely to be covered
Expand

$0 $1,000 $2,000+ -25+% 0% 25% 50% Treatment cost (US$) Efficacy vs. cost for COVID-19 treatments +60 more high-profit drugs PPIs -46% BMS mAbs -36% >$2,000 Darunavir -34% Acetaminophen -29% Cenicriviroc -28% >$2,000 Cannabidiol Lufotrelvir >$2,000 Sargramostim >$2,000 Dexamethasone Lopinavir/ritonavir Ravulizumab >$2,000 Losartan Remdesivir $3,120 Conv. Plasma $5,000 Sarilumab >$2,000 Ibuprofen Masks Molnupiravir mutagenic/teratogenic Tocilizumab Aspirin Favipiravir Paxlovid Ensitrelvir Ratutrelvir Famotidine Vitamin C Sotrovimab $2,100 Colchicine TMPRSS2 i.. NAC Amubarvimab/r.. Vilobelimab $6,350 Azvudine Budesonide Probiotics HCQ Tixagevimab/c.. Zinc Antiandro.. Sleep Metformin Vitamin A Melatonin Bebtelovimab Nitric Oxide Quercetin H1RAs CPC Vitamin D H. Peroxide Exercise Fluvox. Sunlight Curcumin NaHCO₃ N. Sativa Casirivimab/i.. $2,100 Bamlanivimab/e.. Ensovibep >$2,000 PVP-I pH+ Diet Regdanvimab $2,100 Thermotherapy Ivermectin Lifestyle / free No prescription Prescription required High-cost Lowerrisk Higherrisk c19early.org November 2026 USA official early treatments COVID-19 involves the interplay of 500+ host/viral proteins/factors, modulated by many treatments. 0.5% of 12,000+proposed treatments show efficacy with ≥3 studies.Protocols combine treatments, none are 100% effective.c19early analyzes over 6,700 studies for 227 treatments.
$0 $1,000 $2,000+ -20+% 0% 25% 50% Treatment cost (US$) Efficacy vs. cost for COVID-19 treatments +60 more high-profit drugs PPIs -46% BMS mAbs -36% Acetaminophen -29% Cenicriviroc -28% CBD -23% Lufotrelvir -22% Sargramostim Dexame.. Lopinav.. Vit. B9 Ravulizumab Losartan Remdesivir C. Plasma Sarilumab Ibuprofen Masks Molnupiravir mutagenic/teratogenic Tocilizumab Aspirin Favipir.. Paxlovid Ensitrelvir Ratutrelvir Famotidine Vitamin C Sotrovimab Colchicine TMPRSS2 i.. NAC Amubarvimab/r.. Vilobelimab Azvudine Budesonide Probiotics HCQ Tixagev.. Zinc Antiandro.. Sleep Metformin Vitamin A Melatonin Bebtelovimab Nitric Oxide Quercetin H1RAs CPC Vitamin D H. Peroxide Exercise Fluvox. Sunlight Curcumin NaHCO₃ N. Sativa Casirivim.. Bamlan.. Ensovibep PVP-I pH+ Diet Regdanvimab Thermotherapy Ivermectin Lifestyle / free No prescription Prescription required High-cost Lowerrisk Higherrisk c19early.org November 2026 USA official early treatments COVID-19 involves the interplay of500+ host/viral proteins/factors. 0.5% of 12,000+ treatments showefficacy. Protocols combinetreatments. c19early analyzes6,700+ studies for 227 treatments.
Existing treatments have a strong advantage with known pharmacokinetics and safety profiles. New agents are more risky. Long-term risks cannot be known, and known risks may not be acknowledged for some time. For example, molnupiravir's potential risks include the creation of dangerous variants, mutagenicity, carcinogenicity, teratogenicity, and embryotoxicity. Novel treatments saw limited use during the pandemic, partly due to prescription requirements, limited availability, high cost, and, for certain treatments, administration requirements and drug interactions.

Low-cost existing treatments

  • Can reduce risk
  • Known safety profile
  • More widely available
  • Available immediately
  • Can be distributed in advance for immediate treatment

High-profit novel treatments

  • Can reduce risk
  • Inherently risky—long-term and rare side effects unknown
  • High cost limits use
  • Limited production
  • High profit incentivizes unethical behavior
  • Substantial delay for development and testing
  • Delayed treatment due to access barriers
Expand

Studies
6,761
Authors
40,319
Research hours
17 million
Treatments
227
Proposed treatments
12,561
Countries
163
Expand

NIH reviewed only 2.9% of the 1,207 studies for these treatments

reviewednot reviewed
TreatmentReviewedStudiesPercent reviewed
Recommended against
Ivermectin1110610%
Insufficient evidence
Vitamin D51383.6%
Metformin41143.5%
Vitamin C6728.3%
Zinc3407.5%
Not analyzed
HCQ04260%
Diet0300%
PVP-I0210%
Sleep0170%
CPC040%

Analysis of NIH COVID-19 treatment guidelines. NIH added a second reference list with 21 extra ivermectin studies, but no summary, comments, or evidence that they were reviewed. The studies NIH selected are not higher quality—many of the lowest quality and most flawed studies are included.

Expand

TreatmentStudiesBenefitPer life saved$0$2.4M
Melatonin1033%$8
Vitamin D7939%$11
Zinc1835%$14
Vitamin C4419%$18
HCQ25327%$26
Ivermectin5447%$28
Vitamin A446%$30
Colchicine4122%$36
Aspirin688%$45
Curcumin863%$59
Famotidine2017%$94
Metformin7536%$121
Quercetin479%$123
Probiotics1059%$172
Antiandrogens3237%$179
Nitric Oxide812%$363
TreatmentStudiesBenefitPer life saved$0$2.4M
Fluvoxamine1044%$411
Budesonide1125%$887
Inhaled Heparin350%$1,111
Azvudine3030%$1,248
Favipiravir406%$1,935
Tixagev../c..1132%$86K
Regdanvimab763%$140K
Bamlaniv../e..1451%$343K
Sotrovimab1547%$353K
Bebtelovimab460%$738K
Paxlovid4321%$881K
Molnupiravir299%$2.4M
Remdesivir67−1%higher
risk
Conv. Plasma57−3%higher
risk
Dexamethas..13−10%higher
risk
Acetaminophen14−24%higher
risk
PPIs20−40%higher
risk
Sipavibart2−132%higher
risk

Cost estimates are the treatment cost times the median NNT (number needed to treat) from studies reporting mortality results with calculable NNT. Mortality estimates are the results of meta-analysis. Costs are in $US and based on estimated costs for widespread distribution by governments. Results reflect conditions in trials to date, these depend on the population treated, treatment delay, and treatment regimen, e.g., vitamin C results are dominated by very late treatment studies with high control mortality. Dexamethasone shows benefit only for severe/critical patients, and higher risk is seen for earlier treatment.

Expand

COVID-19 treatment protocol efficacy
c19early.org
Expand

0.1% mortality with early treatment vs. 6.2% with late treatment (49× lower)

Early treatment0.1%average mortality2.2% hospitalized
Late treatment6.2%average mortality39% hospitalized
PhysicianCountryPatientsHospitalizedDied
Early treatmenttreatment on presentation
0/360 deaths for treatment within 3 days
Dr. Mohammed Tarek AlamBangladesh10000%
patients up to 84 years old
up to 88yo, 81% comorbidities
Dr. Flavio CadegianiBrazil3,45040.1%00%
Dr. Shankara ChettySouth Africa8,00000%
Dr. Ryan ColeUSA40000%00%
Dr. Marco CosentinoItaly392256.4%10.3%
earlier treatment results were better
Dr. Jeff DavisUSA6,00000%
Dr. DhanajayIndia50000%
Dr. Raphael FurtadoBrazil17010.6%00%
Rabbi Yehoshua GerziIsrael86010.1%00%
Dr. Ellen GuimarãesBrazil50081.6%20.4%
Dr. Syed HaiderUSA4,00050.1%00%
Dr. Sabine HazanUSA1,00000%
Dr. Mollie JamesUSA3,500401.1%10.0%
Dr. Roberta LacerdaBrazil55081.5%20.4%
Dr. Katarina LindleyUSA10055.0%00%
Dr. Ben MarbleUSA150,00040.0%
Dr. Edimilson MigowskiBrazil2,00070.3%20.1%
Dr. Abdulrahman MohanaSaudi Arabia2,73300%
Dr. Carlos NigroBrazil5,000450.9%230.5%
Dr. Benoit OchsLuxembourg80000%
Dr. OrtoreItaly24031.2%00%
Dr. Valerio PascuaHonduras415266.3%10.2%
one patient already on oxygen died
Dr. Sebastian PopRomania30000%
Dr. Brian ProctorUSA869202.3%20.2%
Dr. Didier RaoultFrance8,3152142.6%50.1%
Dr. Karin RiedTurkey23710.4%
up to 99yo, 73% comorbidities
patients up to 86 years old
Dr. Vipul ShahIndia8,00050.1%
Dr. Silvestre SobrinhoBrazil116108.6%00%
Dr. UnknownBrazil957161.7%20.2%
Dr. Vladimir ZelenkoUSA2,200120.5%20.1%
Early treatment236,1812.2%0.1%
Late treatmentno treatment until hospitalization
Dr. Jake Scott (**)USA1,00010010%
Dr. David Uip (*)Brazil2,20085039%542.5%
Late treatment3,20039%6.2%

Early-treatment physicians treated patients on presentation, while late-treatment physicians followed official guidance with treatment only on hospitalization. Groups are not randomized. Results are subject to selection and ascertainment bias and accurate analysis requires details of the patient populations and followup, however the results are consistent across many teams, and consistent with the extensive controlled clinical evidence showing a significant reduction in risk with many early treatments, and complementary/synergistic benefits with combined treatment.

Expand

0 0.25 0.5 0.75 1 1.25 1.5+ PPIs Acetaminophen Cannabidiol Vitamin B9 Remdesivir worse w/longer followup Conv. Plasma Ibuprofen Molnupiravir mutagenic/teratogenic Paxlovid independent trials refused Vitamin C Sotrovimab variant dependent HCQ Zinc Metformin Melatonin Quercetin Vitamin D Exercise Fluvoxamine Sunlight Curcumin PVP-I Alkalinization Diet Regdanvimab Ivermectin Efficacy in COVID-19 studies (pooled effects) Lower risk Increased risk c19early.org November 2026
Expand

0 1000 2000 3000 4000 Age-adjusted cumulativeexcess deaths per million Cumulative excess mortalityduring the COVID-19 pandemic c19early.org November 2026 2020 2021 2022 Omicron becamedominant worldwide Although available, noeffective interventionswere widely adopted Data from Our World in Data, see https://c19early.org/excess.html
Expand

Journals publishing low-cost treatment studies

November 2026

Journals with at least five studies. Impact is the OpenAlex 2-year mean citedness.

  • Each square is one study
  • Impact, higher is better
Journals publishing low-cost treatment studies. Sorted by number of studies.
Treatments
Nutrients
6.45
19 studies
  • Vitamin D14
  • Diet2
  • Exercise1
  • Probiotics1
  • Vitamin C1
Scientific Reports
5.23
18 studies
  • Vitamin D4
  • Metformin3
  • Azvudine2
  • Azithromycin1
  • Diet1
  • H1RAs1
  • HCQ1
  • Indomethacin1
  • Nitric Oxide1
  • Phthalocyan..1
  • Povidone-Iod..1
  • Propolis1
PLOS ONE
3.41
16 studies
  • Colchicine3
  • HCQ3
  • Metformin3
  • Sleep2
  • AgNP1
  • Aspirin1
  • Exercise1
  • Ibuprofen1
  • Ivermectin1
International Journal of Infectious Diseases
2.58
15 studies
  • HCQ5
  • Ivermectin5
  • Ammonium Chloride1
  • Favipiravir1
  • Inosine Pran..1
  • Melatonin1
  • Zinc1
Journal of Clinical Medicine
3.91
13 studies
  • HCQ3
  • Exercise2
  • Antiandrogens1
  • Colchicine1
  • H1RAs1
  • Lactoferrin1
  • Melatonin1
  • NaCl1
  • Sleep1
  • Vitamin D1
Frontiers in Medicine
2.58
13 studies
  • Antiandrogens2
  • Azvudine2
  • Probiotics2
  • Diet1
  • Ivermectin1
  • Nitazoxanide1
  • Povidone-Iod..1
  • Thermotherapy1
  • UDCA1
  • Zinc1
Cureus
1.16
13 studies
  • Ivermectin4
  • Antiandrogens3
  • HCQ2
  • Vitamin C2
  • Famotidine1
  • Metformin1
Frontiers in Pharmacology
5.16
11 studies
  • Azvudine1
  • Camostat1
  • Curcumin1
  • Favipiravir1
  • Fluvoxamine1
  • HCQ1
  • Nigella Sativa1
  • Quercetin1
  • UDCA1
  • Vitamin C1
  • Vitamin D1
BMC Infectious Diseases
3.16
11 studies
  • Ivermectin3
  • HCQ2
  • Azithromycin1
  • Azvudine1
  • Dexamethas..1
  • Diet1
  • Metformin1
  • Vitamin D1
Phytotherapy Research
7.24
10 studies
  • Nigella Sativa4
  • Curcumin3
  • Andrograph..1
  • Colchicine1
  • Propolis1
Journal of Medical Virology
3.50
10 studies
  • Aspirin1
  • Azvudine1
  • Chlorhexidine1
  • HCQ1
  • Ivermectin1
  • Melatonin1
  • Metformin1
  • Montelukast1
  • N-acetylcys..1
  • Nitazoxanide1
Journal of Infection
7.04
9 studies
  • Azvudine2
  • Aspirin1
  • Favipiravir1
  • HCQ1
  • Ivermectin1
  • N-acetylcys..1
  • Nitric Oxide1
  • Vitamin D1
Frontiers in Nutrition
4.45
8 studies
  • Diet5
  • Antiandrogens1
  • Curcumin1
  • Vitamin D1
International Journal of Antimicrobial Agents
4.20
8 studies
  • HCQ4
  • Azithromycin1
  • Ivermectin1
  • Nafamostat1
  • Zinc1
BMJ Open
2.62
8 studies
  • Exercise5
  • Metformin2
  • Zinc1
JAMA Network Open
9.91
7 studies
  • Colchicine2
  • Aspirin1
  • Dexamethas..1
  • Exercise1
  • Fluvoxamine1
  • Sleep1
eClinicalMedicine
12.38
5 studies
  • Azvudine1
  • Camostat1
  • Fluvoxamine1
  • Ivermectin1
  • Nitazoxanide1
Biomedicines
5.28
5 studies
  • Vitamin D2
  • HCQ1
  • Metformin1
  • Probiotics1
Journal of Infection and Public Health
3.92
5 studies
  • Azvudine1
  • Colchicine1
  • Exercise1
  • Favipiravir1
  • Fluvoxamine1
International Journal of Environmental Research and Public Health
3.78
5 studies
  • Vitamin D2
  • Exercise1
  • Lactoferrin1
  • Vitamin C1
Frontiers in Public Health
3.59
5 studies
  • Alkalinization1
  • Exercise1
  • HCQ1
  • Ivermectin1
  • Vitamin D1
Journal of Endocrinological Investigation
3.53
5 studies
  • Vitamin D4
  • Antiandrogens1
Infection and Drug Resistance
2.85
5 studies
  • Azvudine1
  • Diet1
  • Ivermectin1
  • Sleep1
  • Vitamin C1
Open Forum Infectious Diseases
1.21
5 studies
  • HCQ3
  • Favipiravir1
  • Fluvoxamine1
Expand
1 of 17
Treatment results

Random-effects meta-analysis by stage and outcome.

0.4% of treatments show efficacy. Pooled results depend on which stages and outcomes were studied.

2 of 17
What works

Summary of clinical evidence for COVID-19 treatment.

Open full page
3 of 17
Early treatment is critical

As with other viral infections, earlier treatment is more effective.

Open full page
4 of 17
500+ therapeutic targets

COVID-19 involves the interplay of 500+ viral and host proteins and factors, providing many therapeutic targets.

Open full page
5 of 17
12,561 proposed treatments

Studies have reported 12,561 treatments as potentially beneficial for COVID-19.

Open full page
6 of 17
Efficacy was known early

When clinical studies showed that treatments were effective.

Open full page
7 of 17
Country protocols varied widely

Official treatment protocols varied widely around the world.

Open full page
8 of 17
Media coverage was biased

Most low-cost treatment studies were not covered. Coverage favored negative results for low-cost treatments and positive results for high-profit treatments.

Open full page
9 of 17
Efficacy vs. cost

Many treatments reduce COVID-19 risk including low-cost and high-profit treatments. Combined treatment protocols show greater efficacy due to complementary and synergistic mechanisms.

Open full page
10 of 17
17 million hours of research

Studies, treatments, and approvals included in the analysis.

11 of 17
Evidence review was very limited

Authorities did not review most evidence for low-cost treatments.

Open full page
12 of 17
Cost per life saved

0.4% of treatments show efficacy. The cost per life saved varies widely for effective treatments.

Open full page
13 of 17
Treatment protocols in practice

Estimated efficacy of early treatment protocols used by physicians.

Open full page
14 of 17
Physician-reported outcomes

Early combined treatment protocols had lower hospitalization and mortality than late-treatment guidelines.

Open full page
15 of 17
Efficacy overview

Overview of all studies for selected treatments.

Open full page
16 of 17
Interventions were not adopted

No effective intervention was widely adopted. Excess mortality declined only after Omicron became dominant.

Open full page
17 of 17
Journal bias

Journals publishing positive results for low-cost treatments.

Open full page